Circulating tumor DNA (ctDNA) testing has transformed precision oncology by enabling the non-invasive detection of actionable mutations. To facilitate broader clinical adoption and improve testing acc...

Lung-MAP is a precision medicine umbrella trial for patients with advanced non-small cell lung cancer (NSCLC), using genomic screening to match patients to investigational new treatments at more than 900 sites across the U.S. As it moves into its second decade, the trial is undergoing another major update (Lung-MAP 3.0) and greatly broadening the list of approved next-generation sequencing (NGS) genomic tests that can be used to assign patients to a targeted Lung-MAP sub-study.

IASLC presents a one-hour, live session focused on key highlights from the 2024 Hot Topic in Basic & Translational Science Conference. This webinar will ser ...

Zenocutuzumab, a HER2xHER3 bispecific antibody, reduces cell growth in NRG1-rearranged cancer cell lines and xenografts and induces durable clinical responses in patients with NRG1 fusion–positive tum...

The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with limited-stage small cell lung cancer.